This company has been marked as potentially delisted and may not be actively trading. NASDAQ:IMGN ImmunoGen (IMGN) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About ImmunoGen Stock (NASDAQ:IMGN) Get ImmunoGen alerts:Sign Up Key Stats Today's Range$31.23▼$31.2350-Day Range$31.23▼$31.2352-Week Range$3.61▼$31.25VolumeN/AAverage Volume8.78 million shsMarket Capitalization$8.32 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts. As of February 12, 2024, ImmunoGen, Inc. operates as a subsidiary of AbbVie Inc. Read More Receive IMGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ImmunoGen and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IMGN Stock News HeadlinesMindWalk Showcases High-Speed, Lower-Cost LensAI Immunogenicity Screening on AMD-Powered AWS CloudOctober 21, 2026 | tipranks.comImmunoGen Announces Susan Altschuller on FMLA Leave; Interim CFO AppointedJuly 14, 2026 | businesswire.comWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.November 13 at 1:00 AM | Base Camp Trading (Ad)GridAI Technologies completes ImmunogenX ownership rescission transactionJanuary 7, 2026 | tipranks.comEntero Therapeutics Amends Rescission Agreement with ImmunogenXJuly 16, 2025 | tipranks.comBPDCN Market Set for Robust Growth Through 2032 Driven by Targeted Therapies and Rising Disease Awareness | DelveInsightApril 15, 2025 | theglobeandmail.comAbbVie's SWOT analysis: stock outlook strong despite humira lossFebruary 4, 2025 | msn.comAntibody Drug Conjugates Market Size is Expected to Reach USD 25.38 Billion by 2033, Growing at a CAGR of 8.84%: Straits ResearchJanuary 22, 2025 | globenewswire.comSee More Headlines IMGN Stock Analysis - Frequently Asked Questions How were ImmunoGen's earnings last quarter? ImmunoGen, Inc. (NASDAQ:IMGN) issued its quarterly earnings results on Monday, July, 31st. The biotechnology company reported ($0.02) earnings per share for the quarter, beating analysts' consensus estimates of ($0.16) by $0.14. ImmunoGen's revenue for the quarter was up 485.9% compared to the same quarter last year. Read the conference call transcript. Does ImmunoGen have any subsidiaries? ImmunoGen subsidiaries include Hurricane LLC, ImmunoGen BioPharma (Ireland) Limited, ImmunoGen Europe Limited, and ImmunoGen Securities Corp.. What other stocks do shareholders of ImmunoGen own? Based on aggregate information from My MarketBeat watchlists, some other companies that ImmunoGen investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Alibaba Group (BABA), Intel (INTC), Micron Technology (MU) and Novavax (NVAX). Company Calendar Today11/13/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:IMGN CIK855654 Webwww.immunogen.com Phone(781) 895-0600Fax781-895-0611Employees277Year Founded1981Profitability EPS (Trailing Twelve Months)($0.31) Trailing P/E RatioN/A Forward P/E Ratio84.41 P/E GrowthN/ANet Income-$222.93 million Net Margins-25.56% Pretax Margin-25.24% Return on Equity-22.11% Return on Assets-13.53% Debt Debt-to-Equity Ratio0.13 Current Ratio5.70 Quick Ratio5.65 Sales & Book Value Annual Sales$287.61 million Price / Sales28.91 Cash FlowN/A Price / Cash FlowN/A Book Value$0.71 per share Price / Book43.99Miscellaneous Outstanding Shares266,264,000Free Float252,764,000Market Cap$8.32 billion OptionableOptionable Beta1.18 Social Links 10 Best Stocks to Own in Fall 2026AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.Get This Free Report This page (NASDAQ:IMGN) was last updated on 4/10/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredTrump compared today's market to 1929President Trump warned of a 1929-style depression if Democrats won control of Congress. On November 3, they di...USA Capital Gold | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImmunoGen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ImmunoGen With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IMGN Stock Alerts